Trial Profile

Anti-inflammatory Intervention with Dapansutrile (OLT1177®) for Parkinson's Disease Modification (DAPA-PD): A Randomised Double-Blind Placebo-Controlled Phase II Trial.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Feb 2024 New trial record
20 Feb 2024 According to Olatec Therapeutics media release, the company will initiate Phase 2 clinical trial in mid-2024.
20 Feb 2024 According to Olatec Therapeutics media release, Caroline H. Williams-Gray BMBCh MRCP PhD is a Principal Investigator of this study.This single center study will be conducted at the John van Geest Centre for Brain Repair, Department of Clinical Neurosciences at the University of Cambridge and the NIHR Cambridge Biomedical Research Centre.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com